Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept study of RG7774 in treatment-naive diabetic retinopathy
2019-002067-10Phase 2Unknown
- Sponsor
- Roche
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic retinopathy (DR) comparing RG7774 with Placebo (2 arms). Primary endpoint: Proportion of participants with ≥ 2-step improvement in ETDRS diabetic retinopathy severity score at Week 36 (study eye). Status: unknown.
02
Drugs
vicasinabin
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2019-002067-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002067-10.